Cynapsus Therapeutics Inc. (Cynapsus) is a specialty pharmaceutical company developing a drug used to treat the symptoms of Parkinson�s disease. Cynapsus� lead drug candidate, APL-130277, is a reformulation of an approved drug, apomorphine, used to rescue patients from OFF episodes. APL-130277 is a oral formulation of an approved drug (apomorphine) for Parkinson�s patients. APL-130277 is designed to be a convenient, fast-acting rescue for patients experiencing motor fluctuations from off episodes during the day. The reformulation could address a much larger moderate to severe patient population, which represents approximately 25% to 50% of Parkinson�s patients. Apomorphine is only available as an injection, used to rescue patients from OFF episodes. Cynapsus is focused on rapidly maximizing the value of APL-130277 by completing clinical studies in advance of a New Drug Application expected to be submitted in 2014. On December 22, 2011, Cynapsus acquired Adagio Pharmaceuticals Ltd.